methocarbamol has been researched along with Low Back Ache in 10 studies
Methocarbamol: A centrally acting muscle relaxant whose mode of action has not been established. It is used as an adjunct in the symptomatic treatment of musculoskeletal conditions associated with painful muscle spasm. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1206)
methocarbamol : A racemate comprising equimolar amounts of (R)- and (S)-methocarbamol. A centrally acting skeletal muscle relaxant, it is used as an adjunct in the short-term symptomatic treatment of painful muscle spasm. The (R)-enantiomer is more active than the (S)-enantiomer.
2-hydroxy-3-(2-methoxyphenoxy)propyl carbamate : A carbamate ester that is glycerol in which one of the primary alcohol groups has been converted to its 2-methoxyphenyl ether while the other has been converted to the corresponding carbamate ester.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Among ED patients with acute, nontraumatic, nonradicular low back pain, combining naproxen with either orphenadrine or methocarbamol did not improve functional outcomes compared with naproxen+placebo." | 9.27 | A Randomized, Double-Blind, Placebo-Controlled Trial of Naproxen With or Without Orphenadrine or Methocarbamol for Acute Low Back Pain. ( Cisewski, D; Davitt, M; Friedman, BW; Gallagher, EJ; Irizarry, E; Nassery, A; Pearlman, S; Solorzano, C; White, D, 2018) |
| "To compare the 4-week effectiveness and tolerability of an add-on treatment with oral high dose methocarbamol (MET) vs long-acting oral opioid analgesics (LAO) in patients with non-specific low back pain (nsLBP) poorly responsive to recommended 1st line treatments." | 8.12 | COMET - effectiveness and tolerability of methocarbamol versus oral opioid-analgesics as add-on measure in patients with non-specific low back pain refractory to recommended 1st line treatments. A retrospective analysis of depersonalized propensity score ( Mueller-Schwefe, G; Ueberall, MA, 2022) |
| "Muscle relaxants are widely used to treat low back pain (LBP), one of the most frequent health problems in industrialized countries." | 6.80 | [Methocarbamol in acute low back pain. A randomized double-blind controlled study]. ( Emrich, OM; Milachowski, KA; Strohmeier, M, 2015) |
| "Among ED patients with acute, nontraumatic, nonradicular low back pain, combining naproxen with either orphenadrine or methocarbamol did not improve functional outcomes compared with naproxen+placebo." | 5.27 | A Randomized, Double-Blind, Placebo-Controlled Trial of Naproxen With or Without Orphenadrine or Methocarbamol for Acute Low Back Pain. ( Cisewski, D; Davitt, M; Friedman, BW; Gallagher, EJ; Irizarry, E; Nassery, A; Pearlman, S; Solorzano, C; White, D, 2018) |
| "To compare the 4-week effectiveness and tolerability of an add-on treatment with oral high dose methocarbamol (MET) vs long-acting oral opioid analgesics (LAO) in patients with non-specific low back pain (nsLBP) poorly responsive to recommended 1st line treatments." | 4.12 | COMET - effectiveness and tolerability of methocarbamol versus oral opioid-analgesics as add-on measure in patients with non-specific low back pain refractory to recommended 1st line treatments. A retrospective analysis of depersonalized propensity score ( Mueller-Schwefe, G; Ueberall, MA, 2022) |
| "Muscle relaxants are widely used to treat low back pain (LBP), one of the most frequent health problems in industrialized countries." | 2.80 | [Methocarbamol in acute low back pain. A randomized double-blind controlled study]. ( Emrich, OM; Milachowski, KA; Strohmeier, M, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (20.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (10.00) | 29.6817 |
| 2010's | 4 (40.00) | 24.3611 |
| 2020's | 3 (30.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ueberall, MA | 1 |
| Mueller-Schwefe, G | 1 |
| Abril, L | 1 |
| Zamora, C | 1 |
| Cordero, M | 1 |
| Williams, AR | 1 |
| Friedman, BW | 2 |
| Sharifi, M | 1 |
| Abdorazzaghnejad, A | 1 |
| Yazdchi, M | 1 |
| Bahreini, M | 1 |
| Cisewski, D | 1 |
| Irizarry, E | 1 |
| Davitt, M | 1 |
| Solorzano, C | 1 |
| Nassery, A | 1 |
| Pearlman, S | 1 |
| White, D | 1 |
| Gallagher, EJ | 1 |
| Überall, MA | 1 |
| Emrich, OMD | 1 |
| Müller-Schwefe, GHH | 1 |
| Emrich, OM | 1 |
| Milachowski, KA | 1 |
| Strohmeier, M | 2 |
| Brand, RA | 1 |
| MEYERS, GB | 1 |
| URBACH, JR | 1 |
| WEISS, M | 1 |
| WEISS, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Methocarbamol and Orphenadrine for Acute, Non-traumatic, Non-radicular Low Back Pain: A Randomized, Placebo Controlled, 3-armed Study[NCT02665286] | Phase 4 | 240 participants (Actual) | Interventional | 2016-03-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Participants with moderate to severe low back pain after treatment as report on the following ordinal scale: severe, moderate, mild, or none (NCT02665286)
Timeframe: 1 week
| Intervention | Participants (Count of Participants) |
|---|---|
| Placebo | 34 |
| Orphenadrine | 26 |
| Methocarbamol | 31 |
"Change in Roland Morris Disability Questionnaire between baseline and 1 week.~The low back pain functional disability scale is the RMDQ. The RMDQ is a 24-item low back pain functional scale recommended for use in low back pain research.Higher scores signify greater low back-related functional impairment.0= no functional impairment, 24= severe functional impairment." (NCT02665286)
Timeframe: 1 week
| Intervention | units on a scale (Mean) |
|---|---|
| Placebo | 10.9 |
| Orphenadrine | 9.4 |
| Methocarbamol | 8.1 |
Participants still using medication such as analgesics for LBP after treatment (NCT02665286)
Timeframe: 1 week
| Intervention | Participants (Count of Participants) |
|---|---|
| Placebo | 42 |
| Orphenadrine | 40 |
| Methocarbamol | 50 |
The number of participants with affirmative response to the following question: Do you want the same medication combination during a subsequent episode of LBP. This is a patient-centered outcome that allows each individual to determine the desirability of the intervention. (NCT02665286)
Timeframe: 1 week
| Intervention | Participants (Count of Participants) |
|---|---|
| Placebo | 51 |
| Orphenadrine | 53 |
| Methocarbamol | 51 |
1 review available for methocarbamol and Low Back Ache
| Article | Year |
|---|---|
[IGOST guideline for pharmacotherapy of low back pain].
Topics: Amines; Aminopyridines; Analgesics; Analgesics, Opioid; Anti-Anxiety Agents; Antidepressive Agents; | 2010 |
3 trials available for methocarbamol and Low Back Ache
| Article | Year |
|---|---|
Methocarbamol versus diazepam in acute low back pain in the emergency department: a randomised double-blind clinical trial.
Topics: Acute Pain; Diazepam; Double-Blind Method; Emergency Service, Hospital; Humans; Low Back Pain; Metho | 2023 |
A Randomized, Double-Blind, Placebo-Controlled Trial of Naproxen With or Without Orphenadrine or Methocarbamol for Acute Low Back Pain.
Topics: Acute Pain; Administration, Oral; Adult; Anti-Inflammatory Agents, Non-Steroidal; Dose-Response Rela | 2018 |
[Methocarbamol in acute low back pain. A randomized double-blind controlled study].
Topics: Acute Pain; Administration, Oral; Adult; Double-Blind Method; Female; Humans; Low Back Pain; Male; M | 2015 |
6 other studies available for methocarbamol and Low Back Ache
| Article | Year |
|---|---|
COMET - effectiveness and tolerability of methocarbamol versus oral opioid-analgesics as add-on measure in patients with non-specific low back pain refractory to recommended 1st line treatments. A retrospective analysis of depersonalized propensity score
Topics: Adult; Analgesics; Analgesics, Opioid; Humans; Low Back Pain; Methocarbamol; Propensity Score; Regis | 2022 |
The Relative Efficacy of Seven Skeletal Muscle Relaxants. An Analysis of Data From Randomized Studies.
Topics: Acute Pain; Anti-Inflammatory Agents, Non-Steroidal; Baclofen; Diazepam; Humans; Low Back Pain; Meth | 2022 |
[Real-life efficacy and tolerability of methocarbamol in patients suffering from refractory muscle-related low/back pain - Results of a health care research project based on data from the German pain practice registry].
Topics: Cohort Studies; Humans; Low Back Pain; Methocarbamol; Muscle Relaxants, Central; Pain Measurement; P | 2017 |
50 Years Ago in CORR: A clinical study of 46 males with low-back disorders treated with Methocarbamol. Andres Grisolia MD and J.E.M. Thomson CORR 1959;13:299-304.
Topics: Controlled Clinical Trials as Topic; History, 18th Century; History, 19th Century; History, 20th Cen | 2009 |
Methocarbamol for acute low back pain in industry.
Topics: Back Pain; Humans; Industry; Low Back Pain; Methocarbamol; Muscle Relaxants, Central; Occupational D | 1961 |
Methocarbamol in low-back pain: clinical study.
Topics: Back Pain; Biomedical Research; Humans; Low Back Pain; Methocarbamol; Osteopathic Medicine | 1962 |